Olema Oncology’s Upcoming Presentation at Renowned Conference
Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", NASDAQ: OLMA), a pioneering clinical-stage biopharmaceutical company, is gearing up to showcase its progress at the prominent J.P. Morgan Healthcare Conference. Scheduled for early January, this event is notable in the healthcare sector and attracts attention from a myriad of stakeholders, including investors, analysts, and industry leaders.
Leadership Showcase by Sean P. Bohen
At the heart of Olema's presentation will be Sean P. Bohen, M.D., who serves as the company's President and Chief Executive Officer. His insights about Olema's innovative approaches in oncology are highly anticipated, as he will delve into the advancements in targeted therapies for breast cancer and beyond. Held on January 14, 2025, this presentation is a prime platform for discussing the company's strategies and vision for the future.
A Focus on Innovations
Olema's commitment to revolutionizing treatment for breast cancer is reflected in its advanced pipeline of novel therapies. The lead product candidate, palazestrant (OP-1250), is a groundbreaking medication designed as a complete estrogen receptor antagonist and selective estrogen receptor degrader. It is currently undergoing Phase 3 trials in the OPERA-01 study, representing a crucial step toward better treatment outcomes.
A Call for Investor Engagement
The conference will feature a live webcast of Olema's presentation, ensuring that stakeholders can engage with the developments in real time. This initiative underscored Olema's transparency and dedication to keeping shareholders informed about its progress. The recording of the presentation will also be accessible on Olema's Investor Relations website for those unable to attend the live session.
Collaborative Efforts for Future Therapies
Beyond palazestrant, Olema is actively exploring additional avenues in therapeutic development, including a potent KAT6 inhibitor (OP-3136). This dedication to research and development illustrates Olema's unwavering focus on addressing the challenges presented in treating endocrine-driven cancers and improving patient care.
Olema’s Mission and Vision
At its core, Olema Oncology's mission revolves around enhancing the standard of care and significantly improving the outcome for patients afflicted by breast cancer. The company's initiatives hinge on a robust understanding of the mechanisms driving endocrine cancers, paving the way for innovative treatment modalities that can cater to patient needs more effectively.
Headquarters and Research Facilities
Olema is proudly headquartered in the vibrant city of San Francisco, California, with additional operational bases in Cambridge, Massachusetts. This geographical positioning allows for collaboration with leading research institutions and a connection to a thriving biotechnology community.
Contacting Olema Oncology
For inquiries, Olema's dedicated media and investor relations contact is Courtney O'Konek, the Vice President of Corporate Communications. She can be reached directly at media@olema.com. This line of communication ensures that those interested in Olema's journey can easily obtain insights and updates tailored to their interests.
Frequently Asked Questions
What is Olema Oncology known for?
Olema Oncology specializes in developing targeted therapies for breast cancer and other endocrine-driven cancers.
Who will present at the J.P. Morgan Healthcare Conference?
Sean P. Bohen, M.D., President and CEO of Olema, will deliver the presentation.
When will the presentation take place?
The presentation is scheduled for January 14, 2025, at 3:45 p.m. PT.
How can I watch the presentation?
You can view the live webcast on Olema's Investor Relations website.
What is Olema's lead product candidate?
Palazestrant (OP-1250) is Olema's lead product candidate currently in Phase 3 clinical trials.
